Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2+ Metastatic Breast Cancer (MBC)”

147 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 147 results

Large-scale testing (Phase 3)Study completedNCT01808573
What this trial is testing

Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting

Who this might be right for
HER2+ Metastatic Breast Cancer (MBC)
Puma Biotechnology, Inc. 621
Large-scale testing (Phase 3)UnknownNCT02404051
What this trial is testing

Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerBreast CancerHormone Receptor Positive Tumor+2 more
Consorzio Oncotech 745
Early research (Phase 1)Study completedNCT00932373
What this trial is testing

Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing Regimen

Who this might be right for
Metastatic Breast Cancer
Genentech, Inc. 54
Testing effectiveness (Phase 2)Study completedNCT00509769
What this trial is testing

Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Genentech, Inc. 112
Testing effectiveness (Phase 2)UnknownNCT03876587
What this trial is testing

Pyrotinib Combined With Docetaxel in the First-line Treatment of HER2-positive MBC

Who this might be right for
Metastatic Breast Cancer
Zhejiang Cancer Hospital 79
Testing effectiveness (Phase 2)Study completedNCT00134680
What this trial is testing

Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC

Who this might be right for
Metastatic Breast Cancer
Duke University 33
Not applicableEnded earlyNCT02611310
What this trial is testing

Observe Treatment Patterns and Outcomes in Participants in Saudi Arabia With Human Epidermal Growth Factor Receptor 2 (HER2-Positive) Unresectable Locally Advanced or Metastatic Breast Cancer (LA/mBC)

Who this might be right for
Metastatic Breast Cancer
Hoffmann-La Roche 15
Large-scale testing (Phase 3)Study completedNCT01619111
What this trial is testing

DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs

Who this might be right for
HER2-negative Metastatic Breast CancerHER2-positive Circulating Tumor Cells
Prof. Wolfgang Janni 105
Testing effectiveness (Phase 2)Looking for participantsNCT06875128
What this trial is testing

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease

Who this might be right for
Metastatic Breast Cancer in the Liver
Delcath Systems Inc. 90
Large-scale testing (Phase 3)Study completedNCT03901339
What this trial is testing

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Gilead Sciences 543
Testing effectiveness (Phase 2)UnknownNCT02238509
What this trial is testing

Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies

Who this might be right for
Metastatic Breast Cancer
Consorzio Oncotech 154
Not applicableStudy completedNCT04498481
What this trial is testing

TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.

Who this might be right for
Breast Cancer
Pfizer 1
Testing effectiveness (Phase 2)Looking for participantsNCT03213041
What this trial is testing

Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor NegativeEstrogen Receptor PositiveHER2/Neu Negative+4 more
Northwestern University 100
Not applicableStudy completedNCT04001634
What this trial is testing

Dual Anti-HER2 Therapy (Lapatinib and Trastuzumab) Plus Chemotherapy in HER2-positive MBC

Who this might be right for
Breast Cancer
Fudan University 285
Testing effectiveness (Phase 2)Ended earlyNCT03070002
What this trial is testing

Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells

Who this might be right for
Breast Carcinoma Metastatic in the BoneCirculating Tumor Cell CountEstrogen Receptor Positive+3 more
Northwestern University 1
Early research (Phase 1)Study completedNCT00928330
What this trial is testing

Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy

Who this might be right for
Metastatic Breast Cancer
Genentech, Inc. 57
Testing effectiveness (Phase 2)Ended earlyNCT03858972
What this trial is testing

Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC

Who this might be right for
Breast Cancer
Odonate Therapeutics, Inc. 152
Not applicableStudy completedNCT04524728
What this trial is testing

Patterns of Treatment and Outcome of Palbociclib Plus Endocrine Therapy

Who this might be right for
BreastNeoplasm MalignantFemale
Istituti Clinici Scientifici Maugeri SpA 191
Not applicableStudy completedNCT02913456
What this trial is testing

A European Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced (LA) or Metastatic Breast Cancer (mBC) (SAMANTHA)

Who this might be right for
Breast Cancer
Hoffmann-La Roche 629
Testing effectiveness (Phase 2)Looking for participantsNCT05458674
What this trial is testing

Tucatinib+Trastuzumab+Eribulin in HER2+ MBC

Who this might be right for
Breast CancerPretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer
Criterium, Inc. 30
Load More Results